Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Opening Session Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Nov
11
Today In Oncology
CTCL Denileukin Diftitox May Improve HRQoL
Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer
KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
FDA Approves Pimicotinib for Symptomatic TGCT
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo